|
Azacitidine
|
Solid tumors(breast cancer, melanoma, colon cancer)
|
1.0–24.0 mg/kg/day and were given over a minimal period of 8 days
|
I
|
30
|
SD:11/22 PD:11/22
|
1972
|
| |
Solid tumor (breast cancer and other carcinoma)
|
1.6 mg/kg/day on days 1–10 and followed by a maintenance regimen
|
II
|
148
|
–
|
1977
|
|
CC-486
|
Relapsed or refractory solid tumors
|
300 mg/day (oral) on days 1–14 and day 21
|
I
|
20
|
PR:3/8 SD:4/8
|
2018
|
|
Fazarabine
|
Refractory metastatic colon cancer
|
2 mg/m2/h, continuous infusion 72 h every 3–4 weeks
|
II
|
18
|
–
|
1993
|
| |
Refractory solid tumors
|
30 mg/m2, daily bolus 5 times
|
I
|
–
|
–
|
1993
|
|
Decitabine
|
Metastatic solid tumors
|
20–40 mg/m2/day continuous infusion on days 1–3 (28-day cycle)
|
I
|
19
|
PD:14/14
|
2003
|
| |
Solid tumors (ovarian, renal, breast, colon)
|
2 mg/m2/day 7-day continuous infusion (28-day cycle)
|
I
|
10
|
SD:2/9 PD:7/9
|
2005
|
